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2Abstract 
Objectives: To assess salivary, serum biomarkers, and subgingival bacteria as putative 
candidates in the potential association between obstructive sleep apnea syndrome (OSAS) 
and periodontal disease. 
Materials and methods: Fifty-two patients were grouped according to the severity of 
OSAS: 13 participants served as controls, 17 patients had mild-to-moderate OSAS, and 
22 severe OSAS. Serum, saliva, and subgingival plaque samples were collected, clinical 
periodontal parameters recorded. Salivary, serum concentrations of interleukin-6 (IL-6), 
tumour necrosis factor (TNF-α), osteoprotegerin, sRANKL, and apelin were analysed by 
enzyme-linked immunosorbent assay. Bacterial counts were determined by real-time 
QPCR on plaque microbial DNA preparations. 
Results: There was a significant change in the composition of microbes in plaque 
particularly in severe OSAS samples (p<0.01). Statistical analyses indicated significantly 
higher salivary IL-6 levels in both OSAS groups compared to controls (p<0.05). Salivary 
apelin levels were significantly higher in Serum levels of these biomarkers and salivary 
osteoprotegerin, sRANKL levels were similar in the study groups. The incidence and 
duration of apnea positively correlated with clinical periodontal parameters (p<0.05).   
Conclusion: OSAS appeared to alter the tested bacteria in plaque, correlate with 
increasing periodontal disease severity, have additive effect on salivary IL-6.  
Clinical relevance: OSAS is likely to interact with periodontal disease. 
Key words: Apelin; interleukin-6; osteoprotegerin; plaque; obstructive sleep apnea; 
periodontal disease. 
3Introduction 
Obstructive sleep apnea syndrome (OSAS) is characterized by recurrent events of upper 
airway obstruction during sleep associated with accompanying clinical signs and related 
symptoms [1]. OSAS is clinically characterized by repetitive phases of partial (hypopnea) 
or complete (apnea) upper airflow obstruction. This leads to a lowering of haemoglobin 
oxygen saturation and sleep cycle fragmentation [2]. Systemic inflammation and 
increased circulating levels of inflammatory markers have been also associated with 
OSAS [3]. The apnea-hypopnea index (AHI) is the total number of apneas and hypopneas 
per hour during sleep, and it is used to determine both the presence and the severity of 
OSAS [4]. OSAS is indicated when the AHI score is ≥ 5 with accompanying clinical 
symptoms such as excessive daytime sleepiness, loud snoring and nocturnal choking or 
when the AHI score is ≥ 15 without clinical symptoms [5]. An AHI score < 5 is accepted 
within normal limits (non-OSAS), and scores between 5-15, 15-30, and ≥ 30 are 
indicative of mild, moderate, and severe OSAS, respectively [4,5].  
Interleukin-6 (IL-6) is a multifunctional cytokine that has several biological 
activities, such as T-lymphocyte proliferation, B-lymphocyte differentiation and the 
stimulation of immunoglobulin secretion [6]. Notably, IL-6 activates bone resorption 
alone and in conjunction with other bone resorbing agents [7]. Tumour necrosis factor-
alpha (TNF-α) is a potent inflammatory cytokine, which up regulates the production of 
prostaglandin, collagenases, cytokines, cell adhesion molecules and factors related in 
bone resorption [8,9]. Receptor activator of nuclear factor kappa B ligand (RANKL) and 
osteoprotegerin (OPG), members of TNF and TNF receptor superfamily, are also known 
to play important roles in osteoclastogenesis [10]. RANKL first binds RANK and then the 
surface receptors of osteoclasts and preosteoclasts, activates the mature osteoclasts and 
sets up the differentiation of osteoclast progenitors [11]. Besides, OPG is a decoy receptor 
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and activity [12]. IL-6 was found to be higher in plasma samples of OSAS patients 
compared to non-OSAS individuals [3]. IL-6 was also higher in the gingival crevicular 
fluid (GCF) samples of periodontitis patients as it was for TNF-α levels [8,13]. Apelin is a 
peptide hormone, which is thought to have an important role in respiratory physiology 
[14]. Untreated obstructive sleep apnea was associated with elevated plasma apelin levels, 
which restored after continuous positive airway pressure (CPAP) therapy [15].  
Higher prevalence of periodontitis was reported in patients with OSAS [16] and 
major risk factors for periodontitis such as old age, male gender, smoking, alcohol 
consumption, diabetes and obesity [17-19] are generally common in OSAS [20]. 
Furthermore, both periodontitis and OSAS are associated with systemic inflammation 
possibly involving similar pathways and have been suggested to affect development of 
systemic diseases such as cardiovascular disease [21] and diabetes [22]. Increased levels 
of inflammatory markers have been proposed to have a role in periodontal disease and on 
interactions with systemic diseases [23,24].  
It is hypothesized that OSAS may be associated with saliva, serum levels of 
biomarkers, subgingival bacteria counts and clinical periodontal status. Therefore, the aim 
of the present study was to compare saliva, serum IL-6, TNF-α, OPG, sRANKL and 
apelin concentrations and subgingival bacteria counts together with clinical periodontal 
status in patients with or without OSAS. 
Materials and Methods 
Study Population 
Although 159 subjects were screened for inclusion into the study a total of 107 subjects 
were excluded because they did not meet the inclusion criteria, did not wish to participate 
5in the study or for undisclosed reasons (Figure 1). Fifty-two patients (20 females and 32 
males; with an age range of 21 to 64 years) seeking treatment due to sleep apnea-related 
symptoms at the Department of Chest Disease, School of Medicine, Ege University were 
recruited for the study between January 2011 and September 2012  
Seventeen patients (8 females and 9 males; age range 29 to 64 years) were diagnosed to 
have mild-to-moderate OSAS and 22 patients (4 females and 18 males; age range 26 to 61 
years) in the severe OSAS group. Thirteen individuals (8 females and 5 males; age range 
21 to 59 years) were included in the non-OSAS control group. 
Smoking status, alcohol and psychotropic drug use, and anthropometric 
measurements such as body mass index, circumferences of neck, waist and hip, and 
medical histories were carefully evaluated. Pulmonary function tests and blood gas 
analysis were also performed in all subjects. Patients who had diabetes mellitus, 
immunological disorders, arthritis/osteoporosis, history of periodontal intervention within 
the last 6 months or antibiotic treatment within the last 3 months were excluded form the 
study. Eligible individuals had ≥ 20 teeth and were not using removable partial dentures. 
Smoking status of the patients was categorized as current-smoker, former smoker and 
non-smoker. Patients who smoke ≥ 10 cigarettes/day for > 5 years were current-smokers 
and those who smoke <10 cigarettes/day for < 5 years and had quit smoking at least 6 
months prior to enrolment in the study were the former smokers [25]. Non-smokers had 
no history of smoking.  
The study was approved by the Ethics Committee of Ege University, School of 
Medicine with the protocol number 15-1.1/10, and conducted in full accordance with 
ethical principles, including the World Medical Association’s Declaration of Helsinki, as 
revised in 2002. The study protocol was thoroughly explained to all individuals, and 
written informed consent was received from each individual before inclusion in the study. 
6Measurement of Clinical Periodontal Parameters 
Following collection of saliva and serum samples, clinical periodontal parameters were 
measured and recorded by a single examiner (NN) blinded to the sleep apnea status of the 
patients. Before the initiation of the study, intra-examiner calibration was tested and 
validated by an intraclass correlation coefficient of 0.90 for both probing depth (PD) and 
clinical attachment level (CAL) measures. Dichotomous plaque index (PI) [26] (as 
present or absent), PD, and bleeding on probing (BOP; as present or absent within 15 
seconds after periodontal probing) were recorded at 6 sites using a periodontal probe 
(Williams periodontal probe, Hu-Friedy, Chicago, IL, USA ) on each tooth present, except 
the third molars. 
Saliva and Serum Sampling 
Whole saliva samples were collected as previously described by Navazesh [27] simply by 
expectorating into polypropylene tubes, in the morning following an overnight fast during 
which patients were asked not to chew gum or drink anything except water. 500 μL of 
saliva samples were placed in polypropylene tubes following clarification by 
centrifugation (800 g) for 10 min.  
The serum was separated by centrifugation of 5 mL venous blood sample taken 
from the antecubital vein by a standard venipuncture method. Centrifugation was made at 
1500 g for 10 min and 500 μL of aliquots were placed in Eppendorf tubes. Both serum 
and saliva samples were immediately frozen and stored at -80
°
C and thawed immediately 
before the biochemical analyses.  
Subgingival Plaque Sampling 
Subgingival plaque samples were collected as described previously [28] from the two 
7deepest pockets of the dentition. Prior to sampling, the sample teeth were isolated with 
cotton rolls and the sites were cleaned of saliva and supragingival plaque using sterile 
cotton pellets. A sterile paperpoint was quickly inserted to the base of the periodontal 
pocket, left there for 10 s and then removed gently. Maximum care was taken not to 
provoke any bleeding in the adjacent tissues. The two pocket samples were pooled in dry 
Eppendorf tube and the samples were kept at -80
°
C until the microbiological analyses 
were performed.  
Biochemical Analyses 
ELISA or EIA kits were purchased for sRANKL (soluble, uncomplexed RANKL) 
(Peprotech, London, UK), OPG and IL-6 (R & D systems, Abingdon UK), TNF-α 
(Invitrogen, Paisley, UK) and Apelin kit which targets the C-terminus of the 77 amino 
acid peptide and detects all apelin peptides (Sigma, Poole UK). The ELISA assays were 
carried out according to the manufacturers’ recommendations. The lower limits of 
detection for each assay were 1.6 pg/mL for TNF-; 3.2 pg/mL for IL-6; 125 pg/mL for 
sRANKL; 250pg/mL for OPG; and 2.5 pg/mL for apelin.   
Microbiological Analyses 
To provide DNA from known amounts of each test species for use as standards in the 
Real-time quantitative polymerase chain reaction (QPCR) analysis of plaque samples, 
bacterial type strains were grown on agar plates prepared with the appropriate culture 
media, and atmospheric conditions for 24-72 hours (dependent on the microbe).  A single 
colony was then picked and this was grown in liquid culture under the appropriate 
conditions for 24 h. An aliquot was taken to determine the colony forming units.  
Preparation and Assessment of Genomic DNA 
8The Epicentre Masterpure Gram positive DNA isolation kit (Cambio, Cambridge, UK) 
was used to prepare genomic DNA from the test strains (see above) and oral plaque 
sample bacteria from the paper points. Paper points were vortexed for 30 seconds in the 
TE buffer and the manufacturer’s protocol followed. The amount of DNA and the purity 
was checked at 260nm and 280 nm (260/280nm ratio = 1.8–2.0 =good DNA purity) using 
a NANODROP 1000 spectrophotometer (Thermo Renfrew, UK). The DNA in standard 
samples was measured by fluorimetric analysis using the CYquant assay system 
(Invitrogen Paisley, UK) and the value plotted against the number of CFU/ml obtained in 
the original culture and these concentrations were adjusted to use as standards for each 
bacterial assay.   
Real-time quantitative polymerase chain reaction 
A RT-QPCR assay using either TaqMAN or SYBRgreen chemistry (ABI/Invitrogen 
Paisley UK) was used for the detection and quantification of bacterial cell numbers/ CFU 
equivalents in the Real time QPCR. The primers and probes selected for the following 
bacteria were as published in the sources shown: P.gingivalis A. actinomycetemcomitans, 
P. intermedia, P. micra, T. forsythia, F. nucleatum [29-32] T. denticola [33], S. mutans, 
F. nucleatum, S. oralis, A. naeslundi  [34], V. dispar  [35] and were purchased from 
Invitrogen (Paisley, UK) or Eurogentech (Liege, Belgium). 
Statagene MRX III thermal cycler (Agilent, Edinburgh, UK), the TaqMAN assay 
PCR cycling parameters used in the study were 10 min at 95°C, and 40 cycles of 30 s at 
95°C and 1 min at 60°C. The cycles with SYBRgreen were as follows 10 min at 95°C, 
and 40 cycles of 30 s at 95°C and 1 min at 60°C and 1 min at 72°C (used for A. naeslundi 
and V. dispar). All primer sets were validated by running four serial 1/10 dilutions of the 
standard DNA and calculating the efficiency of the reaction (E) where  
E= (10 -1/slope)-1.  
9All reaction efficiencies calculated were acceptable (between 91% and 104%). All primer 
sets failed to amplify the DNA purified from different microbial standards.  
Statistical Analyses 
Microsoft Excel and a commercially available statistical software program (SPSS Inc. 
version 21 IBM, Chicago, USA) was used to analyse the data. After assessing the data 
distribution for each parameter on a Q-Q plot, natural log data transformations were 
performed where necessary. Statistical power calculation was based on ANOVA where 
alpha=0.5, 80% statistical power was attainable when the number in each group 
corresponds to a predicted effect size (n=33 the effect size =0.8, n=21 the effect size =1 
and n= 13 the effect size =1.3). The one-way ANOVA test was performed on the data and 
used to evaluate the differences between groups. Depending on the significance of a 
Levene’s test, a Games-Howell or Tukey test served as the post-hoc test. Chi square and 
Univariate tests were utilized to determine potential confounding factors in the analysis. 
Weighted least squares regression analysis using ANOVA and appropriate post tests, 
were performed in a general linear model to correct for potential confounding factors
including participant gender and periodontal disease for example. The differences in 
bacteria detected in the participant groups were investigated by a principal component 
analysis and summation plot of CFU or proportion of total collected.  
Correlation between the clinical parameters and the microbial analysis, and 
between salivary and serum biochemical data were evaluated with Spearman rho rank 
correlation test. All tests were performed at α = 0.05 significance level.  
Results 
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There was no significant difference in the clinical and demographic parameters between 
the study groups apart from the gender ratios and AHI scores (Table 1). The male/female 
ratio was higher in the severe OSAS group than the mild-to-moderate OSAS and control 
groups (p<0.05) (Table 1). As potential confounding factors, gender and AHI score were 
compensated for in a weighted analysis of the clinical and biochemical data.  
There was a distinct change in the composition of the microbial plaque according 
to the principal component analysis in OSAS patients (Fig.2). All of the selected bacteria: 
A.actinomycetemcomitans, A. naeslundi, F.nucleatum, P. gingivalis, P.intermedia, P. 
micra, S.mutans, S. oralis, T.denticola, T. forsythia, and V.dispar were found in the 
patient groups, but not in every subject (Table 2) within those groups. The total mean 
CFU equivalent counts adjusted to the DNA concentration increased according to OSAS 
severity (Fig. 3A) and the proportion each bacterium tested of the total detected (Fig. 3B) 
was also altered significantly (p<0.01). There was a fall in the number of the test 
microbes found in the mild to moderately affected OSAS patients when compared with 
the control group, but no significant difference was seen in the types of organisms 
detected when compared with the control group.   
Marked increases in Gram negative bacteria tested in plaque samples of the most 
severely affected patients with OSAS and periodontal disease were seen. An increase in 
the Gram positive bacteria tested was also seen in plaque samples in the severe OSAS 
cases (Fig. 3A).   
Salivary IL-6 levels were significantly higher in the OSAS groups compared to the 
non-OSAS control group (Table 2). There was no statistically significant difference in 
salivary IL-6 levels between the two OSAS groups (p<0.05). Salivary apelin levels were 
significantly higher in the severe OSAS group compared to the control group. The levels 
of salivary TNF-, sRANKL, OPG and OPG/sRANKL ratio were all similar in the study 
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groups (Table 3). Serum IL-6 and apelin concentrations were higher in the OSAS groups, 
but there was no statistically significant difference in the serum biomarkers between the 
study groups (Table 3). 
The only significant correlation between salivary and serum biomarkers was found 
in IL-6 levels (rho= 0.311; p=0.038). Salivary IL-6 correlated significantly also with 
predictors of OSAS severity (AHI, oxygen desaturation index). 
The mean length and the longest duration of sleep apnea, the duration of apnea-
hypoapnea correlated with PD, CAL and the number of episodes of apnea correlated with 
CAL (Table 4). 
Discussion 
Despite our intention to recruit more participants to the study, the low number of 
participants due to the high frequency of various systemic diseases in patients with OSAS 
and failure of many potential participants fulfilling the systemic and/or oral inclusion 
criteria is recognised as a major limitation in our study. This also deterred the formation 
of subgroups based on the periodontal status (healthy-gingivitis-chronic periodontitis) 
among the OSAS categories.   
Within the limits of this case-control study, we were able to detect greater 
numbers of periodontally relevant pathogenic micro-organisms in patients with the most 
severe OSAS and these people appeared to show the greatest shift in the composition of 
the microbes detected, which appears to support our hypothesis that OSAS impacts upon 
the colonisation and potential infection of the oral mucosa. A limitation of the QPCR 
approach is that there is a large proportion of the microbial community remains 
unaccounted for.  This may in part explain why we see an apparent fall in the number of 
bacteria detected in Mild to moderate OSAS while the total DNA content remained 
similar. However, it is well documented that the microbial diversity is usually lower in the 
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periodontal disease state than in health [36]. The numbers of periodontally relevant 
pathogens were greater in the patients with severe OSAS, that they made up a 
significantly greater proportion of the oral microbiome than in the people with no OSAS 
or mild/moderate OSAS. This finding makes it tempting to suggest that our results 
support the idea that the diversity of microbes is reduced in severe OSAS. However, 
further analysis of the oral microbiome in such individuals is required to prove this 
hypothesis.  
The influence of OSAS on bacterial colonization and periodontal disease may be 
explained by a low-grade inflammation associated with OSAS together with intermittent 
decrease in oxygenation. These features may contribute to differences in microbial 
ecology, which might influence onset and/or progression of periodontitis. Drying of the 
oral cavity due to mouth breathing in OSAS may also prevent self-cleaning ability of the 
oral mucosa and result in increased bacterial colonization [37]. A higher prevalence of 
periodontitis has been reported in patients with OSAS [1] and both diseases share the 
same risk factors [17-19]. OSAS and periodontitis are also known to affect similar 
systemic diseases such as cardiovascular diseases and diabetes [21,22]. Systemic effects 
on the same diseases might be explained with similar inflammatory pathways, which can 
also be the link between these two chronic diseases. Obesity is another common risk 
factor to be considered in this regard and it has a significant association with periodontitis 
via mechanisms associated with BMI, body fat, and maximum oxygen consumption [38]. 
In the present study, the severe OSAS group had a higher BMI than the control group, but 
the difference was not significant. Larger scale studies may better clarify this possible 
relationship between obesity, OSAS and periodontal diseases. 
Salivary biomarkers may provide information for the assessment of the risk or the 
presence of periodontal disease [39]. Salivary IL-6 levels were significantly higher in the 
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two OSAS groups compared to the control group suggesting that OSAS might be able to 
increase the salivary level of this pro-inflammatory cytokine irrespective of the severity of 
OSAS. Novelty of the present IL-6 finding is the positive correlation between serum and 
salivary concentrations of this cytokine. The salivary IL-6 is likely to be derived from 
serum where it was 7-8 fold higher in concentration, but a contribution may also derive 
from inflammation of local periodontal tissues. Higher salivary IL-6 concentrations have 
been reported in patients with periodontitis [40] and further studies analysing GCF 
samples may shed more light on this hypothesis. It must be noted that it is still unclear 
whether there is a causal relationship between OSAS and the increased salivary IL-6.   
The present findings revealed similar serum levels of IL-6, TNF-α, sRANKL, 
OPG, and apelin in individuals with or without OSAS. Serum sRANKL and OPG data in 
the OSAS patients are documented for the first time. However, previous studies 
demonstrated that the concentrations of IL-6 [12,41] and TNF-α [41] were higher in 
plasma samples of OSAS patients. The present findings did not appear to contradict the 
earlier study, since higher median levels of TNF-α and IL-6 were observed in our 
investigation but levels in OSAS groups were not statistically significantly different from 
the control group serum levels. This apparent discrepancy between TNF-α and IL-6 levels 
in OSAS in different investigations might be explained by possible differences in clinical 
periodontal status as well as demographic variables of the participants particularly as 
circulating levels of IL-6 [42] and TNF-α [43], which have been shown to be higher in 
patients with periodontitis. However, it is just as likely that there were not sufficient 
numbers in our investigation for the results to reach statistical significance.   
Salivary apelin levels in OSAS and non-OSAS patients suggest OSAS increases 
salivary apelin. The highest apelin concentrations were found in saliva samples of the 
severe OSAS group. The mechanism resulting in higher salivary apelin levels in the 
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OSAS groups remain unclear, since there was no statistically significant difference in 
serum apelin concentration. Nevertheless, serum levels appeared to be higher in the 
OSAS groups. It might be questioned whether salivary apelin is derived entirely from the 
circulation. However, mechanisms leading to acquisition and accumulation of apelin in 
saliva remain to be elucidated. As salivary flow rate was not measured in the present 
study, no judgement can be made on this point. Apelin may be released by many cell 
types in the oral cavity in response to bacterial activity. There is also a possibility that 
some other factors in the saliva of OSAS patients are capable of interfering with the 
apelin assay, but this remains unknown. Apelin is a hormone with effects on 
cardiovascular system and glucose homoeostasis [44]. It is expressed by human 
adipocytes and up regulated by insulin and obesity [45], as is IL-6 [46]. Recently, 
periodontitis has been suggested to contribute to adipose tissue inflammation by 
promoting insulin resistance [47]. Both OSAS [48] and periodontitis [47] are associated 
with insulin-resistance, and insulin-induced apelin expression has been demonstrated in 
adipocytes [49]. The presence and severity of periodontitis might influence salivary apelin 
and IL-6 originating from buccal adipocytes may be involved in this response. Further 
studies evaluating apelin levels in GCF of OSAS patients with and without periodontal 
disease in relation with insulin-resistance may help to clarify the possible relation 
between these two diseases. 
Henley et al. [15] demonstrated significantly decreased plasma apelin levels after 
the CPAP therapy suggesting that various hormones such as apelin may play a role in 
OSAS. Zirlik et al. [50] also evaluated the plasma apelin levels in OSAS patients in 
comparison to healthy controls and reported similar plasma apelin levels in study groups. 
The present findings are in line with those of Zirlik et al. [50] as serum apelin levels were 
similar in the OSAS and non-OSAS patients. The present study is the first one to consider 
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the severity of OSAS in regards with serum apelin levels and suggested that OSAS 
severity does not appear to have a prominent effect on circulating apelin level but on 
saliva levels.  Since many cell types including osteoblasts are known to secrete apelin and 
osteoblasts in particular proliferate in response to this molecule [51], there are important 
ramifications which have not been explored in this study particularly as osteoblasts are 
key players in bone metabolism.  
The demographic variables and clinical periodontal parameters were well 
balanced in the present study groups. However, inclusion of both current and former 
smokers may be regarded as a limitation of the present study, as smoking can affect both 
salivary and serum cytokine levels [24]. On the other hand, the numbers of current/former 
smokers appeared to be balanced in the study groups and similar effects of smoking might 
be expected on the biochemical measurements in each study group.   
Conclusion 
In conclusion, the present findings indicate that there is a marked shift in the presence of 
particular oral and periodontally relevant microorganisms in subgingival plaque. This 
finding suggests that OSAS has a bearing on the development of periodontal 
inflammation. A positive correlation between serum and salivary IL-6 concentrations in 
OSAS and the presence and severity of OSAS seem to have little effect on serum IL-6, 
TNF-α, OPG, sRANKL, apelin and salivary TNF-α, OPG, and sRANKL levels despite 
the finding that the number of apnea and duration of apnea correlated with PD and CAL. 
The increase in salivary concentrations of IL-6 and apelin may have an impact on or be 
due to the presence of periodontal disease in patients with OSAS. However, further 
studies with larger sample sizes, which include subgroups based on periodontal diagnosis, 
are required to establish a causal relationship between OSAS and periodontal diseases.  
16
Acknowledgement 
The authors appreciate the help of the sleep technicians Bahar Yörük, Yakup Coşkun and 
Mustafa Kurt in the Sleep Disorders Laboratory, Department of Chest Diseases, School of 
Medicine, Ege University in gathering the data related with systemic health, and to Şefika 
Aysoy and to Esin Şahin for their assistance in the preparation of serum samples of the 
patients.  
Conflict of Interest and Source of funding 
The authors declare that they have no conflict of interest. The study has been funded 
solely by the institutions of the authors.  
17
References 
1. Epstein LJ, Kristo D, Strollo PJ, et al. (2009) Clinical guideline for the evaluation, 
management and long-term care of obstructive sleep apnea in adults. Adult obstructive 
sleep apnea task force of the American Academy of Sleep Medicine. J Clin Sleep Med 
5:263-276.  
2. Gharibeh T, Mehra R. (2010) Obstructive sleep apnea syndrome: natural history, 
diagnosis, and emerging treatment options. Nat Sci Sleep 2:233-255. 
3. Medeiros CA, de Bruin VM, Andrade GM, Coutinho WM, de Castro-Silva C, de Bruin 
PF. (2012) Obstructive sleep apnea and biomarkers of inflammation in ischemic 
stroke. Acta Neurol Scand 126:17-22. 
4. The Report of an American Academy of Sleep Medicine Task Force. (1999) Sleep-
related breathing disorders in adults: recommendations for syndrome definition and 
measurement techniques in clinical research. Sleep 22:667-689. 
5. Iber C, Ancoli-Israel S, Chesson AL, Quan SF. (2007) The AASM manual for the 
scoring of sleep and associated events: rules, terminology and technical specifications. 
Westchester, Illinois: American Academy of Sleep Medicine.  
6. Hirano T, Akira S, Taga T, Kishimoto T. (1990) Biological and clinical aspects of 
interleukin 6. Immunol Today 11:443-449. 
7. Ishimi Y, Miyaura C, Jin CH, et al. (1990) IL-6 is produced by osteoblasts and induces 
bone resorption. J Immunol 145:3297-3303. 
8. Bastos MF, Lima JA, Vieira PM, Mestnik MJ, Faveri M, Duarte PM. (2009) TNF-
alpha and IL-4 levels in generalized aggressive periodontitis subjects. Oral Dis 15:82-
87. 
9. Okada H, Murakami S. (1999) Cytokine expression in periodontal health and disease. 
Crit Rev Oral Bio Med 9:248-266. 
10. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. (1999) 
Modulation of osteoclast differentiation and function by the new members of the tumor 
necrosis factor receptor and ligand families. Endocr Rev 20:345-357. 
11. Lacey DL, Timms E, Tan HL, et al. (1998) Osteoprotegerin ligand is a cytokine that 
regulates osteoclast differentiation and activation. Cell 93:165-276.  
12. Boyle WJ, Simonet WS, Lacey DL. (2003) Osteoclast differentiation and activation. 
Nature 423:337-342.  
18
13. Ribeiro FV, de Mendonça AC, Santos VR, Bastos MF, Figueiredo LC, Duarte PM. 
(2011) Cytokines and bone-related factors in systemically healthy patients with chronic 
periodontitis and patients with type 2 diabetes and chronic periodontitis. J Periodontol 
82:1187-1196. 
14. Hosoya M, Kawamata Y, Fukusumi S, et al. (2000) Molecular and functional 
characteristics of APJ. Tissue distribution of mRNA and interaction with the 
endogenous ligand apelin. J Biol Chem 275:21061-21067. 
15. Henley DE, Buchanan F, Gibson R, et al. (2009) Plasma apelin levels in obstructive 
sleep apnea and the effect of continuous positive airway pressure therapy. J Endocrinol 
203:181-188. 
16. Seo WH, Cho ER, Thomas RJ, An SY, Ryu JJ, Kim H, Shin C. (2013) The association 
between periodontitis and obstructive sleep apnea: a preliminary study. J Periodont 
Res 48:500-506. 
17. Arbes SJ, Jr. Agustsdottir H, Slade GD. (2001) Environmental tobacco smoke and 
periodontal disease in the United States. Am J Public Health 91:253-257. 
18. Timmerman MF, van der Weijden GA. (2006) Risk factors for periodontitis. Int J Dent 
Hyg 4:2-7. 
19. Filoche SK, Cornford E, Gaudie W, Wong M, Heasman P, Thomson WM. (2010) 
Smoking, chronic periodontitis and smoking cessation support: reviewing the role of 
dental professionals. N Z Dent J 106:74-77.  
20. Young T, Skatrud J, Peppard PE. (2004) Risk factors for obstructive sleep apnea in 
adults. JAMA 291:2013-2016. 
21. Peker Y, Kraiczi H, Hedner J, Löth S, Johansson A, Bende M. (1999) An independent 
association between obstructive sleep apnoea and coronary artery disease. Eur Respir J 
14:179-184. 
22. Shaw JE, Punjabi NM, Wilding JP, Alberti KGMM, Zimmet PZ. (2008) Sleep-
disordered breathing and type 2 diabetes: a report from the International Diabetes 
Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract 81:2-
12. 
23. Howells GL. (1995) Cytokine networks in destructive periodontal disease. Oral Dis 1: 
266-270. 
24. Gümüş P, Nizam N, Lappin DF, Buduneli N. (2014) Saliva and serum levels of B-cell 
activating factors and tumor necrosis factor-alpha in periodontitis patients. J 
Periodontol 85:270-280. 
19
25. Erley KJ, Swiec GD, Herold R, Bisch FC, Peacock ME. (2006) Gingival recession 
treatment with connective tissue grafts in smokers and non-smokers. J Periodontol 
77:1148-1155. 
26. Quigley GA, Hein JW. (1962) Comparative cleansing efficiency of manual and power 
brushing. JADA 65:26-29. 
27. Navazesh M. (1993) Methods for collecting saliva. Ann NY Acad Sci 694: 72-77. 
28. Buduneli N, Baylas H, Buduneli E, Turkoglu O, Kose T, Dahlen G. (2005) Periodontal 
infections and pre-term low birth weight: a case-control study. J Clin Periodontol 32; 
174-181. 
29. Boutaga K, van Winkelhoff AJ, Vandenbroucke-Grauls CM, Savelkoul PH. (2003)  
Comparison of real-time PCR and culture for detection of Porphyromonas gingivalis in 
subgingival plaque samples. J Clin Microbiol 41:4950-4984.  
30. Boutaga K, Savelkoul PH, Winkel EG, van Winkelhoff AJ. (2007) Comparison of 
subgingival bacterial sampling with oral lavage for detection and quantification of 
periodontal pathogens by real-time polymerase chain reaction. J Periodontol 78:79-86.  
31. Boutaga K, van Winkelhoff AJ, Vandenbroucke-Grauls CM, Savelkoul PH. (2005)  
Periodontal pathogens: a quantitative comparison of anaerobic culture and real-time 
PCR. FEMS Immunol Med Microbiol 45:191-199.  
32. Boutaga K, van Winkelhoff AJ, Vandenbroucke-Grauls CM, Savelkoul PH. (2006) 
The additional value of real-time PCR in the quantitative detection of periodontal 
pathogens. J Clin Periodontol 33:427-433. 
33. Yoshida A, Kawada M, Suzuki N, Nakano Y, Oho T, Saito T, Yamashita Y. (2004) 
TaqMan real-time polymerase chain reaction assay for the correlation of Treponema 
denticola numbers with the severity of periodontal disease. Oral Microbiol Immunol 
19:196-200. 
34. Periasamy S, Chalmers NI, Du-Thumm L, Kolenbrander PE. (2009) Fusobacterium 
nucleatum ATCC 10953 requires Actinomyces naeslundii ATCC 43146 for growth on 
saliva in a three-species community that includes Streptococcus oralis. Appl Environ 
Microbiol 75:3250-3257. 
35. Ammann TW, Belibasakis GN, Thurnheer T. (2013) Impact of early colonizers on in 
vitro subgingival biofilm formation. PLoS One 8:e83090. 
36. Jorth P, Turner KH, Gumus P, Nizam N, Buduneli N, Whiteley M. (2014)  
Metatranscriptomics of the human oral microbiome during health and disease. MBio 
5:e01012-14. 
20
37. Alexander AG. (1970) Habitual mouthbreathing and its effect on gingival health. 
Parodontologie 24:49-55. 
38. Saito T, Shimazaki Y, Sakamoto M. (1998) Obesity and periodontitis. New Eng J Med 
339;482-483.  
39. Buduneli N, Kinane D. (2011) Host-derived diagnostic markers related to soft tissue 
destruction and bone degradation in periodontitis. J Clin Periodontol 38 Suppl 11:85-
105. 
40. Costa PP, Trevisan GL, Macedo GO, et al. (2010) Salivary interleukin-6, matrix 
metalloproteinase-8, and osteoprotegerin in patients with periodontitis and diabetes. J 
Periodontol 81:384-391. 
41. Inancli HM, Enoz M. (2010) Obstructive sleep apnea syndrome and upper airway 
inflammation. Recent Pat Inflamm Allergy Drug Discov 4:54-57. 
42. Marcaccini AM, Meschiari CA, Sorgi CA, et al. (2009) Circulating interleukin-6 and 
high-sensitivity C-reactive protein decrease after periodontal therapy in otherwise 
healthy subjects. J Periodontol 80:594-602. 
43. Iwamoto Y, Nishimura F, Soga Y, et al. (2003) Antimicrobial periodontal treatment 
decreases serum C-reactive protein, tumor necrosis factor-alpha, but not adiponectin 
levels in patients with chronic periodontitis. J Periodontol 74:1231-1236. 
44. Beltowski J. (2006) Apelin and visfatin: Unique “beneficial” adipokines upregulated in 
obesity? Med Sci Monit 12:RA112-119. 
45. Boucher J, Masri B, Daviaud D, et al. (2005) Apelin, a newly identified adipokine up-
regulated by insulin and obesity. Endocrinology 146:1764-1771. 
46. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. (2007) Visceral fat adipokine 
secretion is associated with systemic inflammation in obese humans. Diabetes 
56:1010-1013. 
47. Su Y, Wang D, Xuan D, Ni J, Luo S, Xie B, Zhang J. (2013) Periodontitis as a novel 
contributor of adipose tissue inflammation promotes insulin resistance in a rat model. J 
Periodontol 84:1617-1626. 
48. Harsch IA, Hahn EG, Konturek PC. (2005) Insulin resistance and other metabolic 
aspects of the obstructive sleep apnea syndrome. Med Sci Monit 11:RA70-75. 
49. Glassford AJ, Yue P, Sheikh AY, et al. (2007) HIF-1 regulates hypoxia and insulin-
induced expression of apelin in adipocytes. Am J Physiol Endocrinol Metab 
293:E1590-596. 
21
50. Zirlik S, Hauck T, Fuchs FS, Neurath MF, Konturek PC, Harsch IA. (2011) Leptin, 
obestatin and apelin levels in patients with obstructive sleep apnoea syndrome. Med 
Sci Monit 17:CR159-164. 
51. Xie H, Tang SY, Cui RR, et al (2006) Apelin and its receptor are expressed in human 
osteoblasts. Regul Pept. 134:118-125.  
22
Table 1: Demographic variables and periodontal parameters of the patients. Values are 
given as mean ± standard deviation.  
Control 
Mild-to-Moderate 
OSAS 
Severe OSAS 
Age (years) 43.23 ± 9.08 49.88 ± 11.47 45.36 ± 9.81 
Gender (F/M) (n) 8/5 8/9 4/18* 
Smoking (Non- 
smoker/smoker/ex- 
smoker)
4/5/4 12/3/2 11/7/4 
Number of teeth 
present 
24.54 ± 3.23 25.29 ± 3.31 26.23 ± 2.29 
PD (mm) 2.05 ± 0.45 2.41 ± 0.49 2.50 ± 0.79 
CAL (mm) 2.22 ± 0.63 2.68  ± 0.72 3.04 ± 1.29 
PI 1.44 ± 0.55 1.27 ± 0.55 1.61 ± 0.85 
Periodontal Status 
Healthy/Gingivitis/ 
Periodontitis
6/6/1 4/8/5 8/6/8 
Sites (%) PD > 4mm 2.10 ± 5.05 7.02 ± 11.21 11.69 ± 13.96 
BOP (%) 24.73 ± 17.63 33.11 ± 16.65 33.43 ± 24.50 
AHI (events/h) 2.64 ± 1.82
†
 17.24 ± 7.90
‡
 67.49 ± 30.39 
BMI (kg/m
2
) 31.71 ± 4.56 31.85 ± 5.32 34.18 ± 7.24 
*
Statistical significant difference compared to control group (p=0.024). 
† 
Statistical significant difference compared to OSAS groups (p<0.0001). 
‡ 
Statistical significant difference compared to control and severe OSAS groups 
(p<0.0001).  
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Table 2:  Proportion of PCR positive individuals for each of the tested microorganisms. 
Microbe Control mild/moderate 
OSAS 
severe OSAS 
A. actinomycetemcomitans 7/13 54% 17/19 89% 16/22 73% 
A. naeslundi 12/13 92% 19/19 100% 20/22 91% 
F. nucleatum 11/13 85% 12/19 63% 15/22 68% 
P. gingivalis 8/13 62% 15/19 79% 17/22 77% 
P. intermedia 4/13 31% 3/19 16% 2/22 9% 
P. micra 8/13 62% 13/19 68% 13/22 59% 
S. oralis 11/13 85% 18/19 95% 18/22 82% 
S. mutans 13/13 100% 19/19 100% 22/22 100% 
T. denticola 5/13 38% 12/19 63% 13/22 59% 
T. forsythus 8/13 62% 13/19 68% 15/22 68% 
V. dispar 11/13 85% 17/19 89% 15/22 68% 
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Table 3: Salivary and serum cytokine levels in OSAS and non-OSAS patients (pg/mL).
Saliva  Control  Mild/Moderate Severe 
Median (q1 - q3) Mean ± std Median (q1 - q3) Mean ± std Median (q1 - q3) Mean ± std 
TNF  5.3(5.1 - 9.5) 6.8 ± 2.2 7.6(4.7 - 9.15) 10.6 ± 10.1 8.6(4.4 - 13.1) 10.2 ± 9.8 
sRANKL 319.7(131.4 - 808.8) 482.8 ± 442.9 290.2(156.3 - 739.3) 466.3 ± 404.5 231.3(125.8 - 342.2) 465.7 ± 391.6 
OPG 830.5(329.7 – 1057.0) 712.0 ± 376.9 709.1(536.0 - 829.7) 689.3 ± 255.8 785.6(614.1 - 955.5) 679.5 ± 250.9 
OPG/RANKL 0.55(0.1 – 2.2) 1.5 ± 2.2 0.4(0.2 - 1.4) 1.3 ± 2.4 0.3(0.1 - 0.5) 1.3 ± 2.3 
IL-6 8.8 (6.9 - 11.9) 8.5 ± 2.5 14.4(9.2 - 17.2)* 18.1 ± 13.1* 13.1(8.7 - 20.7)* 16.6 ± 12.3* 
Apelin 20.3(9.9 - 141.4) 103.3 ± 204.8 35.3(6.5 - 245.8) 222.5 ± 387.2 223.1(20.6 - 877.2)* 210.2 ± 378.4*
Serum Control Mild/Moderate Severe
TNF 91.2(58.7 - 97.1) 91.3 ± 64.6 95.1(74.5 - 106.4) 86.7± 40.5 69.2(30.5 - 128.4) 99.5 ± 64.63 
sRANKL 607.1(319.0 - 718.8) 559.9 ± 296.6 514.9(207.0 - 754.5) 532.0 ± 371.1 635.7(276.6 - 678.9) 536.2 ± 358.9 
OPG 1107.0(534.2 - 1308.0) 980.0 ± 475.9 1026(933.7 - 1488.0) 1195.0 ± 425.6 1121.0(802.9 - 1535.0) 1142.0 ± 461.6 
OPG/RANKL 0.6(0.3 - 1.5) 1.0 ± 1.4 0.4(0.1 - 0.8) 0.6 ± 0.6 0.6(0.2 - 1.2) 0.7 ± 0.6 
IL-6 80.4(59.8 – 104.7) 82.4 ± 27.2 101.5(92.9 - 115.7) 99.1 ± 42.5 84.9(36.7 - 151.3) 99.2 ± 41.1 
Apelin 39.0(19.3 - 51.20) 37.7 ± 21.9 54.7(25.2 - 141.9) 69.2 ± 58.9 50.1(19.8 - 65.8) 65.5 ± 58.8 
* Significantly higher than the control group (p<0.05).  
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Table 4. The correlations between sleep apnea parameters and clinical periodontal parameters.
Correlations PD CAL
 Rho P Rho P 
No.of apnea 0.272 0.052 0.315 0.023 
Mean apnea (sec) 0.386 0.006 0.416 0.003 
Longest apnea (sec) 0.322 0.022 0.331 0.019 
Duration of apnea-hypopnea (min) 0.362 0.009 0.403 0.003 
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Legends: 
Figure 1
Figure 2. Principal component analysis (PC) of A. actinomycetemcomitans, A. naeslundi, F. nucleatum, 
P. gingivalis, P. intermedia, P. micra, S oralis, S. mutans, T. denticola, T. forsythus and V. dispar in 
sulcal and subgingival plaque of controls (C) without OSAS (circles), mild/moderate (m)OSAS 
(triangles) and severe (s)OSAS (squares) combined with varying levels of periodontal disease, gingivitis 
(+G)  or periodontitis (+P) with increasing severity shown by increased intensity of grey in of the symbol. 
The chart shows a plot of the greatest variance in natural log transformations of bacterial counts plotted 
against the second greatest variance value of this data set. A shift in the composition of microbial plaque 
particularly in subjects with sOSAS and periodontal disease is indicated.  
Figure 3.  The stacked bar graphs indicate the cumulative numbers (A) and relative proportions of the 
sum (B) of A. actinomycetemcomitans (A.actinom), A. naeslundi, F. nucleatum, P. gingivalis,  
P. intermedia, P. micra, S oralis, S. mutans, T. denticola, T. forsythus and V. dispar in sulcal and 
subgingival plaque of controls without OSAS, mild/moderate OSAS and severe OSAS.  
* Significant increase in microorganisms and in Gram negative microorganisms compared with the 
    Control and Mild/moderate OSAS, p<0.001. 
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Figure 1. Flow Diagram 
Assessed for eligibility (n=159) 
Excluded  (n= 107) 
 Not meeting inclusion criteria (n= 92) 
 Declined to participate (n=9) 
  Other reasons (n= 6) 
Analysed  (n=52) 
 Excluded from analysis (n=0)
Depending on AHI scores (n=52) 
 Non-OSAS (n=13)
 mild-to-moderate OSAS (n=17) 
 Severe OSAS (n=22)
Grouping 
Analysis
Enrolled (n= 52) 
Enrollment
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Figure 2: Principal component analysis  
Key: 
C = Non-OSAS control group 
mOSAS = mild/moderate OSAS 
sOSAS= Severe OSAS 
+G – with gingivitis 
+P = with periodontitis 
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Figure 3: Detection of selected microorganisms in periodontal sulcal and subgingival plaque 
